Actividad in vitro de caspofungina frente a aislados clínicos de Candida resistentes a fluconazol en pacientes con infección por el VIH

  title={Actividad in vitro de caspofungina frente a aislados cl{\'i}nicos de Candida resistentes a fluconazol en pacientes con infecci{\'o}n por el VIH},
  author={Victoria Ortiz de la Tabla-Ducasse and Mar Masi{\'a}-Canuto and Coral Mart{\'i}n-Gonz{\'a}lez and F{\'e}lix Guti{\'e}rrez-Rodero},
  journal={Enfermedades Infecciosas Y Microbiologia Clinica},
2 Citations
In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran
Caspofungin appears more effective in vitro against Iranian fluconazole-resistant Candida isolates and some other yeasts.
Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
Echinocandins are proved to exhibit excellent activity to the Candida species most frequently involved in human infections, except Candida parapsilosis.


In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
ABSTRACT Caspofungin is an echinocandin antifungal agent with broad-spectrum activity against Candida and Aspergillus spp. The in vitro activities of caspofungin against 3,959 isolates of Candida
Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.
Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.
In a multivariate analysis, the number of episodes and duration of fluconazole therapy were independent predictors of resistance.
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Growth kinetic studies of MK-0991 against Candida albicans and Candida tropicalis isolates showed that the compound exhibited fungicidal activity within 3 to 7 h at concentrations ranging from 0.06 to 1 microg/ml (0.25 to 4 times the MIC).
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora
  • J. Rex, M. Pfaller, A. Barry
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections.
Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Caspofungin appeared to be efficacious therapy for some patients with esophageal candidiasis who were clinically refractory to flu Conazole or infected by with reduced susceptibility to fluconazole in vitro.
Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients.
It is indicated that treatment with antituberculous drugs, previous tuberculosis, and fluconazole exposure are the strongest determinants for development of oropharyngeal colonization or infection by flu Conazole-resistant Candida strains in HIV-infected patients.
Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998
An international program of surveillance of bloodstream infections (BSI) in the United States, Canada, and Latin America detected 306 episodes of candidemia in 1997 and 328 episodes in 34 medical centers in 1998, with resistance to fluconazole and itraconazole observed in C. glabrata and C. krusei.
Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.